life science research tools market size, growth and …life science research tools market size,...

Life science research tools

market size, growth and

trends (2006-2016)

April, 2012 2nd edition

Information contained in this market report is believed to be reliable

at the time of publication. DeciBio is not soliciting any action based

on the information contained in this report. See appendix section for

complete disclosures.

DeciBio LLC

1428 Kelton Ave

Suite 201

Los Angeles, CA 90024

Phone: 213-915-8283

Email: [email protected]

www.decibio.com

Agenda

• Introduction

• Executive summary

• Pure genomics tools

• Pure proteomics tools

• Cell biology tools

• Other analytical technologies

• Other supplies and technologies

• Appendix

2

Given the current macroeconomic headwinds, DeciBio forecasts that the LS

research tools market will grow at ~4% p.a. in the next 5 years

This report provides an overview of the life sciences research tools market from 2006 to 2016. Life sciences research tools companies

offer instruments, reagents and services to scientists in academic, BioPharma and applied market laboratories. Top vendors include

Agilent, Bio-Rad, EMD Millipore, Life Technologies (Invitrogen / Applied Biosystems), Roche, Sigma-Aldrich and Thermo Fisher; smaller

emerging players are highlighted as well (e.g., genomics players [Fluidigm, Raindance, Oxford Nanopore, NABSys, GnuBio]).

Segmenting the market by technology, we estimate that the life science research tools market reached $37.4B in 2011, and is expected to

grow ~4% p.a. in the next 5 years. Many reports on individual technologies report bullish growth rates of 5%-20% for Academic,

BioPharma and Applied market customers (and excluding in vitro diagnostics). While our analysis confirms that applied market might

experience double digit growth for many technologies, current market size estimates for these customers do not support an overall market

growth of 10%+ for the overall life science research tools sector. This is especially true in light of the current global economic slowdown

(including in India and China) and continued sovereign-debt crisis in Europe. A review of public fillings and guidance from the top players

in this space –as well as an analysis of the funding reality in Academia and BioPharma– confirms this outlook. This report evaluates which

technologies are expected to capture and loose market share in this mid-single digit growth rate market.

In this second edition, we updated our analysis to reflect the most current market sales and trends in 5 broad segments:

1) Pure genomics technologies: qPCR, next generation sequencing (NGS) / third generation sequencing (3GS), microarrays, PCR, CE

sequencing, molecular biology tools, digital PCR;

2) Pure proteomics technologies: protein isolation and analysis, ELISA, protein production, western blots and protein microarrays;

3) Cell biology technologies: discovery services, basic cell biology reagents, flow cytometry, transfection and electroporation, media and

sera, microscopy, cell culture equipment, whole cell analysis, cells and tissues, high content imaging;

4) Other analytical technologies: liquid chromatography, mass spectroscopy, structural analysis methods, in vivo study, spectroscopy,

multiplex technologies, label free technologies;

5) Other supplies and technologies: lab supplies and disposables, glassware, automation, sample preparation, LIMS, magnetic beads.

For each of these 35 subsegments, we present an analysis detailing sales of instruments and reagents for 2006, 2011 and 2016. In

addition, we detail market drivers and moderators, market trends, a high level end-customer breakdown (Academic, BioPharma and

Applied markets customers) and key competitors. Many of these technologies are increasingly used for clinical diagnostics purposes.

Therefore, we briefly cover the size, growth and trends of the in vitro diagnostics and molecular diagnostics markets.

All data are based on manufacturer sales as publically reported, and interviews with life sciences experts in academic, BioPharma and

applied market laboratories.

Online abstract

3

This report is divided in the following sections

4

Introduction 1

Agenda 2

Abstract 3

Table of contents 4

2nd edition: what’s new? 5

Included/excluded technologies 6

Definition (product types) 7

Definition (end-customer types) 8

Methodology 9

Technology timeline 10

Executive summary 11

LS market by category 12

LS market by geography 13

LS market by end-customer 14

LS market by product type 15

R&D funding trends 16

LS players strategic bets 17

LS players and operational excellence 18

Pure genomics tools 19

LS genomics market by technology 20

qPCR 21

Microarrays 22

NGS / 3GS 23

PCR 24

CE sequencing 25

Molecular biology 26

Digital PCR 27

Pure proteomics tools 28

LS proteomics market by technology 29

Protein isolation 30

ELISA 31

Protein production 32

Western blots 33

Protein microarrays 34

Cell biology tools 35

LS Cell biology tools market by technology 36

Discovery services 37

Basic cell biology reagents 38

Flow cytometry 39

Transfection and electroporation 40

Media and sera 41

Microscopy and automation 42

Cell culture equipment 43

Whole cell imaging 44

Cells and tissues 45

High content imaging 46

Other analytical tools 47

LS analytical tools by technology 48

Liquid chromatography 49

Mass spectroscopy 50

Structural analysis 51

Other analytical tools (continued)

In vivo study 52

Spectroscopy 53

Multiplex technologies 54

Label free technologies 55

Lab supplies and disposables 56

Overall LS supplies market by technology 57

Basic supplied and disposables 58

Glassware 59

Liquid handling and automation 60

Sample preparation 61

LIMS 62

Magnetic beads 63

Appendix 64

Positioning of key players 65

Revenue guidance from key players 66

NIH funding analysis 67

IVD market 68

MDx market 69

CE instrument decommission 70

NGS market by product type 71

Abbreviations 72

Related DeciBio reports 73

Disclosure 74

Table of contents

2nd edition: What’s new?

• Incorporated the latest trends in the life science

research tools market

• Added 8 new supplies & technologies to this market:

• Structural analysis technologies (electron microscopy,

NMR and X-ray systems)

• Spectroscopy

• Label free technologies

• Glassware

• Liquid handling and automation

• LIMS

• Added 19 pages, primarily with new analysis, and a

description of our methodology and classification

• Expanded our analysis of key players in this space

Updated content

5

• Reassessed market trends for:

• NGS in light of recent developments (e.g., $1,000 genome)

• dPCR given increased visibility of market players and

difficulty for the opportunity to materialize (due in part to the

lack of clear applications); resulted in decreased overall

opportunity size

• Cell-based discovery services given continued aggressive

outsourcing from BioPharma; resulted in increased growth

rate estimates

• Adjusted market size and growth for some markets

• Microarrays: given identified niche opportunities

• ELISA: Decreased market size 2010/11 market size

(~20%) due to identified analysis bias; accelerated growth

due to faster than expected adoption of multiplex ELISA

• Mass spectrometry: Adjusted market size, given expected

use from interviewee feedback

• Sample preparation: Decreased market growth, given

underperformance of market leader (Qiagen)

• Refined instrument/reagent revenue contributions for

some technologies

• qPCR

• Laboratory supplies

• Transfection and electroporation

• Cell culture equipment

Updated numbers*

• Updated all market numbers for 2011 market size

based on secondary research and latest trends

• Market growth rate generally adjusted downward given

increased focus on funding sources (and economic

backdrop [e.g., in Europe]) during our interview campaign

• Estimated instrument / reagent revenue contribution

for 3 technologies based on interviewee feedback

• Liquid chromatography

• Mass spectrometry

• in vivo analysis

Updated numbers

Note: * Most significant changes only; additional adjustments have been made based on primary and secondary research data analysis

This report assesses the WW market size, growth and trends of the life sciences

(LS) research tools space; it includes and excludes the following technologies

• In vitro diagnostics Point-of care tests

Clinical chemistry

Immunoassays / Radioimmunoassays

Hematology** / Coagulation assays

Microbiology

Molecular diagnostics

• Medical tools and safety Hospital equipment

Surgical tools / Safety devices

Blood collection products

• Other life science technologies Synthetic biology (including nucleic acid

synthesis)

Electrophysiology and patch clamp

Single cell analysis

• Other niche markets***

• Combinatorial chemistry

• Medical devices

Note: * Ordered by estimated 2011 market size ** Some of these tools can be used to study both genomics and proteomics *** Small markets such as laser capture microscopy, digital barcoded arrays (i.e., Nanostring) Source: DeciBio analysis

• Pure genomic tools qPCR

Microarrays

Next generation sequencing (NGS) /

Third generation sequencing (3GS)

PCR

CE Sequencing

Molecular biology

Digital PCR

• Pure proteomic tools Protein isolation and analysis

Protein production

ELISA

Western blots

Protein microarrays

• Cell biology tools Discovery services

Basic cell biology reagents

Flow cytometry

Transfection and electroporation

Media and sera

Microscopy

Cell culture equipment and

plasticware

Whole cell imaging

Cells and tissues

High content imaging (HCI)

• Other analytical technologies and

sample preparation** Liquid chromatography

Mass spectroscopy

Structural analysis

in vivo study

Spectroscopy

Multiplex technologies

Label free technologies

• Lab supplies and disposables Basic supplies and disposables

Glassware

Liquid handling and automation

Sample preparation

LIMS

Magnetic beads

Technologies included* Technologies excluded

6

Market sizes for each of the 35 technologies are reported as instrument or

reagent revenues

Note: * Exceptions exist (e.g., pipettes, some cell counters) Source: DeciBio analysis

7

Instruments (Instruments, service

contract and software)

• Instruments include systems and platforms used for sample preparation or analysis,

and that typically require a source of energy (e.g., 110V / 220V, battery)*

Example instruments include sequencers, mass spectrometers, PCR thermal cyclers or pH meters

• Many users purchase a service contract (or annual maintenance agreement) to

“insure” the instrument and guarantee timely repair when necessary

Service contracts typically vary from 8-15% of instrument purchase price (per year)

• Software run complex instruments often required to be connected to a computer for

operation and data analysis

Reagents (Reagents, consumables

and services)

Product types

• Reagents and kits are products that are used (in combination or not with an

instrument) in order to analyze a sample

Example reagents include PCR primers, antibodies or cells

• Consumables are products used in order to conduct the experiment, but that are not

necessarily directly involved in the analytical process

Example consumables include pipette tips, gloves or glassware

• Services are experiments conducted for a lab by a life science research tools

manufacturer (not another laboratory, core facility or CRO)

Example services include sequencing services from Complete Genomics, bioproduction services

from Life Technologies, discovery services from Millipore

Customers were separated in 3 groups: academic and government labs,

BioPharma, and applied markets

Note: * BioPharma includes instrument and reagent purchased by CRO (not price of services charged to Biopharma) ** Centre national de la recherche scientifique (CNRS) in France, National Health Service (NHS) in the U.K. *** Example foundations: HHMI, Gates foundation, Keck / Kavli / Doris Duke foundation) **** Applied market customers adopt technologies xx-xx years after academic customers, but before clinical customers Source: DeciBio analysis

8

Academic and government BioPharma* Applied markets

Definition

• Non-profit customers and centers

relying on government funding,

primarily from the NIH in the U.S.**

• Basic and translational research

• Incentive to innovate: High (very early

technology adopter)

• For profit organizations developing

drugs for treatment of diseases such

as cancer or Alzheimer’s

• Preclinical research (and some use

during clinical trials)

• Incentive to innovate: Moderate to high

(early technology adopter)

• For profit or government funded-

institutions and laboratories

• Testing (and some basic research

[e.g., in AgBio])

• Incentive to innovate: Moderate (late

technology adopter****)

Example

customers

• Yale U. professor (academia)

• USCD associate professor (academia)

• Missouri U. core lab (academia)

• NIH post-doctoral fellow (government)

• Pfizer (large pharma)

• Novartis (large pharma)

• Amgen (large biotech)

• Actellion (small pharma)

• Covance (CRO)

• DuPont (AgBio)

• Vet. diagnostic labs (animal health)

• Central science lab (biosecurity)

• IEH labs (food safety)

• FBI lab services (Forensics)

Market size /

growth (2011)

$xx.xB (~xx% of total) /

xx% (2011-16F CAGR)

$xx.xB (~xx% of total) /

xx% (2011-16F CAGR)

~$xx.xB (~xx% of total) /

xx% (2011-16F CAGR)

Key trends

driving and

moderating

growth

+ Continued contribution of ARRA

funding spend through 2012

+ Increased awareness of not-for-profit

funding alternatives***

- Cutback in funding, given austerity

measures in developed countries

- Increased uncertainty in funding,

given decreased success rate in NIH

grant funding (from ~30% to ~20%)

+ xxx

+ xxx

- xxx

- xxx

+ xxx

+ xxx

- xxx

Customer types

We used a combination of primary and secondary research to compile data

presented in this report

Note: * Overall: 23 interviews in the U.S., 10 in Europe and 4 in the rest of the world; ** 5 post-doctoral fellows *** All discussion started with discussion of the funding environment, and interviewees were asked to reassess future technology

usage based on their current funding (e.g., what would they stop doing to fund new large scale RNA-Seq projects) Source: DeciBio analysis

9

We built a bottom-up market model by technology; growth rates obtained from interviewee feedback and

secondary research guidance were triangulated with the reality reflecting the current funding environment***

Data and analysis

Primary research Secondary research

• Interviews with 37 experts*

17 academic professors and post-doctoral fellows**

from leading institutions worldwide (~60% in the U.S.)

7 lab directors and senior scientists in large Pharma

4 lab directors and senior scientists in small to mid-

size biotech companies

5 lab directors and scientists in applied markets

4 life science business experts / professionals

• Interview structure

Funding

Current and future activity

Key players and technologies

Trends and unmet needs

• Company financial information

10-K / 10-Q

Company presentations

Press releases

• Company technical information

Company website

Company publications and posters

Company technical sheets

• Other sources

PubMed

Peer-reviewed publications and scientific posters

Government reports and databases (e.g., NIH reporter)

Healthcare conferences (e.g., JP Morgan, Cowen)

While many technologies discussed in this report were invented within the last

~30 years, a few methods have been used for more than a century

Note: * Introduced by Qiagen; ** High content imaging Source: DeciBio analysis

10

Key events for selected technologies

discussed in this report

1983: PCR Invention

1986: qPCR Invention

1990: microarrays Invention

1999: NGS 454 Life Sciences

founded

1995: dPCR Invention

Genomics

Proteomics

2000: Prot. microarrays Invention

Cell biology

1996: HCI** Cellomics founded

1995: Multiplex techs Luminex founded

Other techs

1986: Mag beads Dynal founded 1900: Chromatography

1919: Mass spectroscopy

1931: Electron microscopy

1945: NMR

Invention

<1975 1980 1985 1990 1995 2000

1986: Sample prep First plasmid kit*

1965: Flow cytometry Invention

1984: Label free (SPR) Biacore founded

1975: Western blot Invention

1590: Microscopy

1873: Fluorescent microscopy Invention

1971: ELISA Invention

Agenda

• Introduction







• Appendix

11

6.0 7.5 9.0

6.0 7.5

9.0 6.0

7.5

9.0 6.0

7.5

9.0

6.0

7.5

9.0

$-

$10

$20

$30

$40

$50

2006 2011E 2016F

Other technologies Other analytical techs

Cell biology Pure proteomics

Pure genomics

As defined in this report, the worldwide life science research tools market is

expected to grow at xx% p.a. from ~$xx.xB in 2011 to reach ~$xx.xB in 2016

Note: * Excluding IVD (sales of IVD/510(k)/CE-marked tests [see Appendix]) Source: DeciBio analysis

WW life sciences research tools

market by category (2006-16F)*

Billions of dollars

CAGR

(2006-11) (2011-16F)

xx%

xx%

xx%

xx%

xx%

xx%

Category Selected

Technologies

2011E

Market

size ($B)

2011-16

CAGR

Other

technologies

Lab supplies xx xx

Glassware xx xx

Automation xx xx

Sample preparation xx xx

LIMS xx xx

Magnetic beads xx xx

Other analytical

technologies

Liquid chromato. xx xx

Mass spectrometry xx xx

Structural analysis xx xx

In vivo study xx xx

Spectroscopy xx xx

Multiplex techs xx xx

Label free techs xx xx

Cell biology

Discovery services xx xx

Basic reagents xx xx

Flow cytometry xx xx

Transfection & electroporation xx xx

Media and sera xx xx

Microscopy xx xx

Cell culture equipment xx xx

Whole cell analysis xx xx

Cells and tissues xx xx

High content imaging xx xx

Pure proteomics

technologies

Protein isolation & analysis xx xx

Protein production xx xx

ELISA xx xx

Western blots xx xx

Protein microarrays xx xx

Pure genomics

technologies

qPCR xx xx

Microarrays xx xx

NGS / 3GS xx xx

PCR xx xx

CE Sequencing xx xx

Molecular biology xx xx

Digital PCR xx xx

Attractive Neutral Unattractive

“… [Next generation sequencing] is poised to become the key technology to

deliver on the promise of personalized medicine and to drive the routine use of

genomic[s] in medical practice […] We believe that in a not very distant future,

infants will be sequenced at birth […] And as we get down toward $1,000 genome,

we think that, that opportunity is going to break wide open and generate [revenue]

greater than the loss from the pricing changes …”

- CEO, Illumina (Earnings call, 02/07/2012)

xx%

xx%

xx%

xx%

xx%

xx%

Dummy data

10.0 13.0 15.0

10.0

13.0 15.0

10.0

13.0

15.0

$-

$10

$20

$30

$40

$50

2006 2011E 2016F

Applied markets Biopharma Academia

… And growth in applied markets in the U.S. and abroad, given low- to mid-

single digit growth from academic and BioPharma customers



market by end customer (2006-16F)*

Billions of dollars

CAGR

(2006-11) (2011-16F)

xx%

xx%

xx%

xx%

• Academic and Biopharma customers have

experienced a significant decrease in R&D

funding during the 2009 recession

xxx

xxx

• Key LS technologies used in applied markets

include

xxx

xxx

xxx

• Applied markets tend to be xx-xx years behind

academic customers with regards to

technology adoption

xxx

xxx

• Applied markets considered in this study

include: AgBio, Animal health, Biosecurity,

Environmental testing, Food safety, Forensics,

Human identification, Pharma QA/QC

xx%

xx%

xx%

xx%

“… We saw a significant slowdown in [the academic and government] market in

Q3 [2011, due to] uncertainty around the future of NIH budgets, as well as the

budget crisis in many European countries […] Turning to Pharma and Biotech, we

had a very strong finish to the year in this customer set driven by demand in

research, development and manufacturing. In research applications, we had solid

momentum in mass spectrometry. […] Demand from industrial-implied markets

generated strong growth in both revenues and bookings during [Q4 2011] .…”

- CEO, Thermo Fisher (Earnings call, 02/01/2012)

14

Dummy data

In the technology life cycle, instruments generate revenue first, followed by

increased reagent pull-through as the instrument installed based expands


15.0 18.0

22.0

15.0

18.0

22.0

$-

$10

$20

$30

$40

$50

2006 2011E 2016F

Instruments, service contracts and Software

Reagents, consumables and Services


market by product type (2006-16F)*

Billions of dollars

CAGR

(2006-11) (2011-16F)

• Key analytical Instruments include:

Liquid chromatographs (~$xxxM)

Mass spectrometers (~$xxxM)

Structural analysis instruments, including electron

microscopes, NMR and X-ray systems (~$xxxM)

Basic instruments, such as balances, pipettes and

centrifuges (~$xxxM)

Lab automation instruments (~$xxxM)

Spectrometers (~$xxxM)

Optical and fluorescent microscopes (~$xxxM)

NGS sequencers (~$xxxM)

qPCR thermal cyclers (~$xxxM)

Flow cytometers (~$xxxM)

• Key reagents include

qPCR assays (~$xxxM)

Cell based assay discovery services (~$xxxM)

Basic cell biology reagents (~$xxxM)

Microarray chips (~$xxxM)

Protein isolation and analysis reagents (~$xxxM)

Media and sera (~$xxxM)

Sample preparation kits and reagents (~$xxxM)

Cell culture equipment (~$xxxM)

ELISA plates (~$xxxM)

Molecular biology reagents (~$xxxM)

• xxx

“… The instrument:reagent split is an interesting question. What we’ve seen in

recent years is many companies being willing to compromise on margins for

instruments in order to increase placement […] Once instruments are placed,

reagent pull through can be significant. For instance, just a few years ago,

Illumina reported >$500K per year per placed microarray reader, and this

number is in the $300K range for their high-end sequencing platforms. And

that’s not including additional revenues for instrument service contracts…”

- Director, top tier research tool company

xx%

xx%

xx%

xx%

xx%

xx%

15

Dummy data

Agenda

• Introduction







• Appendix

19

The worldwide LS research tools genomics market is expected to grow at xx%

p.a., driven by strong double-digit growth in next generation sequencing

Note: * Excluding IVD (sales of IVD/510(k)/CE-marked tests [see Appendix]) ** Availability of bench sequencers (e.g., Life Technologies, Illumina) with lower throughput than standard NGS platforms Source: DeciBio analysis

1.0 1.2 1.4 1.0 1.2 1.4 1.0

1.2 1.4 1.0

1.2 1.4

1.0 1.2

1.4 1.0

1.2

1.4

$-

$2

$4

$6

$8

$10

$12

2006 2011E 2016F

digital PCR Molecular biologyCE Sequencing PCRNGS / 3GS MicroarraysqPCR

CAGR

(2006-11) (2011-16F)

xx%

xx%

xx%

xx%

xx%

xx%

xx%


genomics market (2006-16F)*

Billions of dollars

20

• Drivers and moderators

+ xxx

+ xxx

+ xxx

+ xxx

- xxx

- xxx

- xxx

- xxx

• Key trends

xxx

xxx

xxx

• End customers

Academic customers (~xx%)

BioPharma (~xx%)

Applied markets (~xx%)

• Key competitors

Life technologies, Roche, Illumina, Bio-Rad

Group Technology Key application

PCR

PCR Standard amplification

qPCR Gene expression analysis, genotyping

dPCR Same as qPCR, with lower detection limit

Sequencing NGS / 3GS de novo sequencing, resequencing, RNA-Seq

CE sequencing Sequence validation

Other Microarrays Gene expression analysis, genotyping

xx%

xx%

xx%

xx%

xx%

xx%

xx%

The ~$x.xB qPCR market is expected to grow at xx% p.a., driven by xxx and

xxx

Note: * Excludes MDx revenues; see Appendix; Source: Company 10-Ks and press releases, DeciBio interviews and analysis

960 20

30 10

20

30

$-

$10

$20

$30

$40

$50

$60

$70

2006 2011E 2016F

Instruments Reagents

xx%

xx%

xx%


+ xxx

+ xxx

+ xxx

+ xxx

- xxx

- xxx

- xxx

• Key trends

xxx

xxx

xxx

xxx

xxx

• End customers

Academic customers (~xx%), BioPharma (~xx%),

Applied markets (~xx%)

• Key competitors

Life technologies (Applied Biosystems), Roche, Bio-

Rad, xxx, xxx, xxx

WW life sciences qPCR market

(2006-16F)*

Millions of dollars

“… Despite the availability of NGS or microarrays, qPCR continues to be used a

discovery tool in hypothesis driven experiments […] However, people think

about it more as a validation tool downstream of microarrays or NGS …”

- Assistant Professor, Harvard Medical School

21

Description and applications: quantitative Polymerase Chain Reaction

(qPCR) is a variation of PCR that utilizes reagents (e.g., primers, DNA

binding dyes) that are fluorescently tagged in order to follow the reaction in

real time. This method is used primarily for genotyping applications mRNA

levels quantification or nucleic acid monitoring (e.g., viral load analysis).

Due to his more quantitative nature, this method has been used widely in

clinical settings (not included in market size above; see appendix).

CAGR

(2006-11) (2011-16F)

Additional growth offset by

patent expirations and

availability of cheaper

alternatives to TaqMan

xx%

xx%

xx%

Dummy data

Agenda

• Introduction







• Appendix

28

The ~$xxM ELISA market is expected to grow at xx% p.a., driven by continued

conversion of competitive to sandwich ELISA, as well as adoption of kits

Note: * Excluding IVD (sales of IVD/510(k)/CE-marked tests [see Appendix]); Source: Company 10-Ks and press releases, DeciBio interviews and analysis

10 20

30 10

20

30

$-

$10

$20

$30

$40

$50

$60

$70

2006 2011E 2016F

Instruments Reagents

xx%

xx%

xx%


+ xxx

+ xxx

- xxx

- xxx

• Key trends

xxx

xxx

xxx

xxx

xxx

• End customers

Academic customers (~xx%)

BioPharma (~xx%)

Applied markets (xx%)

• Key competitors

Life Technologies, Techne (R&D Systems), BD

Biosciences, Millipore, Cell Signaling Technologies

WW life sciences ELISA

market (2006-16F)*

Millions of dollars

“… An increasing number of companies offer ELISA kits, and quality is

improving. We don’t bother home brewing anymore. We recently tried CST

PathScan kits and the results are extremely reproducible …”

- Associate Professor, UCSD

32

Description and applications: Enzyme-linked immunosorbent assay

(ELISA), is an analytical biochemistry assay that uses reagents (often an

antibody) attached to a plate to detect the presence of a substance (often a

protein) in a sample. ELISA is a common tool and is used in applications

ranging from basic research (especially for protein quantification), quality

control (detection of contaminants) all the way to clinical diagnostics (not

included in market numbers above)

CAGR

(2006-11) (2011-16F)

Dummy data xx%

xx%

xx%

3GS: Third generation sequencing

AgBio: Agricultural biotechnology

ARRA: American Recovery and Reinvestment Act

ATCC: American Type Culture Collection

BRIC: Brazil, India, China

CE Sequencing: Capillary electrophoresis sequencing

CAGR: Compound annual growth rate

CGH: Comparative genomic hybridization

CNV: Copy number variation

COLD PCR: Co-amplification at lower denaturation

temperature-PCR

CMO: Contract manufacturing organization

CRO: Contract research organization

Dx: Diagnostics

ELISA: Enzyme-linked immunosorbent assay

GPCR: G protein-coupled receptors

HCI: High content imaging

HHMI: Howard Hughes Medical Institute

HLA: Human leukocyte antigen

HPLC: High-performance liquid chromatography

HPV: Human papillomavirus

HTS: High throughput screening

IVD: in vitro diagnostic

KO: Knock-out

LGC: Large genome center

LIMS: Laboratory information management system

LS: Life sciences

MALDI-TOF: Matrix-assisted laser desorption/ionization-time

of flight

miRNA: microRNAs

MDx: Molecular diagnostics

MHC: Major histocompatibility complex

MRSA: Methicillin-resistant Staphylococcus aureus

NA: Nucleic acid

ncRNA: non-coding RNAs

NGS: Next generation sequencing

NIH: National institute of Health

NMR: Nuclear magnetic resonance

OEM: Original equipment manufacturer

p.a.: Per annum

PCR: Polymerase chain reaction

PGM: Personal genome machine

Pharma QA/QC: Pharma quality assurance and quality control

POC: Point-of-care

QA / QC: Quality assurance / quality control

qPCR: quantitative PCR

R&D: Research and Development

RNA: Ribonucleic acid

ROW: Rest of world

RUO: Research use only

SNP: Single nucleotide polymorphism

SPR: Surface plasmon resonance

TBD: To-be-determined

UCSD: University of California San Diego

UCSF: University of California San Francisco

UHTS: Ultra-high throughput screening

WW: Worldwide

Major abbreviations used in this report

72

If interested in this report, consider the following DeciBio reports

73

Find related DeciBio reports on our website: www.decibio.com:

Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by

Provider (http://www.decibio.com/NGS)

Fluidigm Due Diligence: Company Profile, SWOT Analysis and Market Opportunity

(http://www.decibio.com/FLDM)

Molecular Diagnostics: Market Size, Segmentation, Growth and Opportunities

(http://www.decibio.com/MDx)

Molecular Diagnostics: Market Size, Segmentation, Growth and Opportunities

(http://www.decibio.com/MDx)

Qiagen Due Diligence: Company Profile, SWOT Analysis and Market Opportunity

(http://www.decibio.com/Qiagen)

http://www.decibio.com/

http://www.decibio.com/NGS

http://www.decibio.com/FLDM

http://www.decibio.com/MDx




Information contained in this market report is believed to be reliable at the time of

publication. However, DeciBio does not warrant its accuracy or completeness.

Opinions, estimates and other information constitute the judgment of DeciBio, and can

be subject to change without notice.

DeciBio is not soliciting any action based on the information contained in this report.

This report is provided for informational purposes only and should not be construed as

a call for action.

DeciBio and its collaborators may own equity and/or securities related to any company

cited in this report, and engage in transactions inconsistent with this report.

This report and any access to it are intended to the buyer only. This report is published

by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any

form is prohibited without the prior consent of DeciBio, LLC.

This report may contain digital controls and custom watermarks for tracking purposes.

Please inquire about site license pricing for your institution by contacting

[email protected] before sharing this document.

Disclosures

74 Gold edition

mailto:[email protected]

life science research tools market size, growth and …life science research tools market size,...

Documents